Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 4/20 | 0.34 |
| ▸ | MMP13 | P45452 | 3/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5957505 | 1.00 | ADAM17 (0.34) | ADAM17MMP13MMP8MMP2DPP4 | |
| SCHEMBL5949439 | 0.78 | ADAM17 (0.41) | ADAM17MMP13MMP2 | |
| SCHEMBL5949429 | 0.78 | ADAM17 (0.41) | ADAM17MMP13MMP2 | |
| SCHEMBL5957737 | 0.77 | ADAM17 (0.35) | ADAM17MMP13MMP8MMP2DPP4 | |
| SCHEMBL5957544 | 0.75 | MMP13 (0.33) | ADAM17MMP13MMP8MMP2 | |
| SCHEMBL6201448 | 0.74 | MMP7 (0.35) | ADAM17MMP13MMP8MMP2DPP4 | |
| SCHEMBL6201446 | 0.74 | MMP7 (0.35) | ADAM17MMP13MMP8MMP2DPP4 | |
| SCHEMBL5957536 | 0.74 | MMP7 (0.55) | ADAM17MMP13MMP8MMP2 | |
| SCHEMBL6166245 | 0.72 | ACACB (0.34) | ADAM17MMP13MMP8MMP2 | |
| SCHEMBL5957537 | 0.72 | ACACB (0.34) | ADAM17MMP13MMP8MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063783-A1 | Sulphonylpiperidine derivatives containing an alkenyl or alkynyl moiety for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1531821-A2 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNYL MOIETY FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Astrazeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004006927-A2 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNLY MOIETY FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063783-A1 | Sulphonylpiperidine derivatives containing an alkenyl or alkynyl moiety for use as matrix metalloproteinase inhibitors | MMP9, MMP2, TIMP3 | ADAM17 5/4885MMP13 23/4885MMP8 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.